This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use

News

Bionow members are welcome to submit PR items to this newsroom for all to see. An animated website user guide is available here which demonstrates how members can add news directly to the website after logging in. 

Whether currently a member or not, to keep in touch with all relevant news and information make sure you are registered to receive our newsletter.

Byotrol 

Byotrol gets green light for product sales in the US

10 May 2018

Daresbury hygiene firm Byotrol has received approval for its germ-killing product in the US, and received its first orders to retail on online giant Amazon.

> Read More

Lancaster University 

Director appointed to Health Innovation Campus

3 May 2018

Lancaster University is pleased to announce that Dr Sherry Kothari will be the new Director of its Health Innovation Campus.

> Read More

BOYDS 

Boyds awarded Queen’s Award for Enterprise

3 May 2018

Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products and devices for patient benefit, has today been recognised with one of the UK’s most prestigious business awards – The Queen’s Award for Enterprise, International Trade for Outstanding Short Term Growth in overseas sales for the last three years.

> Read More

University of Liverpool 

£450k Boost for Bowel Cancer Research in Liverpool

1 May 2018

Researchers from the University of Liverpool have been awarded a £450K grant from Cancer Research UK to help further develop a machine that can ‘smell’ cancer.

> Read More

 

Glythera appoints Professor Kerry Chester to SAB

30 April 2018

Glythera Limited (Glythera), the next-generation antibody drug conjugate (ADC) development company, today announces that it has appointed Professor Kerry Chester to its Scientific Advisory Board (SAB). Professor Chester’s appointment strengthens the Company’s SAB and will help shape its portfolio of ADCs for targeting previously untreatable cancers.

> Read More